Top

Osteoporosis International

Published in:

01-07-2013 | Short Communication

Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment

Authors: A. D. Anastasilakis, S. A. Polyzos, P. Makras, A. Gkiomisi, M. Savvides, A. Papatheodorou, E. Terpos

Published in: Osteoporosis International | Issue 7/2013

Abstract

Summary

Activin-A is expressed in bone and seems to regulate osteoclastogenesis. In this study, serum activin-A was increased in postmenopausal women with low bone mass and was positively correlated to age and negatively to lumbar spinal bone mineral density (BMD). Serum activin-A levels did not change 3 months after zoledronic acid infusion.

Introduction

The aims of the study were to evaluate prospectively the circulating activin-A levels in postmenopausal women with low bone mass and explore possible correlations with clinical and laboratory data, as well as the 3-month effect of zoledronic acid infusion.

Methods

Postmenopausal women with low bone mass assigned to receive zoledronic acid infusion (Patients, n = 47) and age-matched, postmenopausal women with normal bone mass (Controls, n = 27) were recruited on an outpatient basis. Main outcome measurement was serum activin-A levels.

Results

Serum activin-A was higher in patients at baseline compared to controls (p < 0.001) and activin-A in the serum of patients and controls was positively correlated with age (Spearman’s coefficient of correlation [rs] = 0.325; p = 0.005) and negatively with lumbar spinal (LS) BMD (rs = −0.425; p < 0.001). In multiple linear regression analysis, only age (B = 8.93; 95 % CI = 4.39–13.46; p < 0.001) was associated with serum activin-A levels at baseline, independent from group (patients or controls), previous anti-osteoporotic treatment, LS BMD and follicle-stimulating hormone. Circulating activin-A levels were not affected 3 months after zoledronic acid infusion.

Conclusions

Serum activin-A is increased in postmenopausal women with low bone mass compared with postmenopausal women with normal bone mass and is positively correlated to age and negatively to LS BMD.

Available only for authorised users

de Kretser DM, O'Hehir RE, Hardy CL, Hedger MP (2012) The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol Cell Endocrinol 359:101–106PubMedCrossRef

Payne C, King J, Hay D (2011) The role of activin/nodal and Wnt signaling in endoderm formation. Vitam Horm 85:207–216PubMedCrossRef

Luisi S, Florio P, Reis FM, Petraglia F (2001) Expression and secretion of activin A: possible physiological and clinical implications. Eur J Endocrinol 145:225–236PubMedCrossRef

Toulis KA, Anastasilakis AD, Polyzos S, Makras P (2011) Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Hormones (Athens) 10:174–195

Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden AG, van der Spek PJ, Visser JA, de Jong FH, Pols HA, van Leeuwen JP (2007) The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 21:2949–2960PubMedCrossRef

Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC (2002) Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 143:74–83PubMedCrossRef

Nicks KM, Perrien DS, Akel NS, Suva LJ, Gaddy D (2009) Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, activin and inhibin. Mol Cell Endocrinol 310:11–20PubMedCrossRef

Hashimoto M, Shoda A, Inoue S, Yamada R, Kondo T, Sakurai T et al (1992) Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin. J Biol Chem 267:4999–5004PubMed

Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y (1999) Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem 75:206–214PubMedCrossRef

10.

Vale W, Wiater E, Gray P, Harrison C, Bilezikjian L, Choe S (2004) Activins and inhibins and their signaling. Ann N Y Acad Sci 1038:142–147PubMedCrossRef

11.

Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra J, Weissleder R, Anderson KC, Scadden DT, Raje N (2010) Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 107:5124–5129PubMedCrossRef

12.

Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu L, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M (2006) FSH directly regulates bone mass. Cell 125:247–260PubMedCrossRef

13.

Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, Dimopoulos MA (2012) Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol 23:2681–2686

14.

Leto G (2010) Activin A and bone metastases. J Cell Physiol 225:302–309PubMedCrossRef

15.

Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, Fajardo RJ, Kumar R, Underwood KW, Seehra J, Bouxsein ML, Baron R (2010) A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 46:1082–1088PubMedCrossRef

16.

Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML (2009) Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24:744–752PubMedCrossRef

17.

Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661PubMedCrossRef

18.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612PubMedCrossRef

19.

Drake MT, McCready LK, Hoey KA, Atkinson EJ, Khosla S (2010) Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab 95:5063–5068PubMedCrossRef

20.

Loots GG, Keller H, Leupin O, Murugesh D, Collette NM, Genetos DC (2012) TGF-β regulates sclerostin expression via the ECR5 enhancer. Bone 50:663–669PubMedCrossRef

21.

Fuller K, Bayley KE, Chambers TJ (2000) Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun 268:2–7PubMedCrossRef

22.

Baccarelli A, Morpurgo PS, Corsi A, Vaghi I, Fanelli M, Cremonesi G, Vaninetti S, Beck-Peccoz P, Spada A (2001) Activin A serum levels and aging of the pituitary-gonadal axis: a cross-sectional study in middle-aged and elderly healthy subjects. Exp Gerontol 36:1403–1412PubMedCrossRef

23.

Singhellakis PN, Malandrinou FC, Psarrou CJ, Danelli AM, Tsalavoutas SD, Constandellou ES (2011) Vitamin D deficiency in white, apparently healthy, free-living adults in a temperate region. Hormones (Athens) 10:131–143

Title: Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment
Authors: A. D. Anastasilakis
S. A. Polyzos
P. Makras
A. Gkiomisi
M. Savvides
A. Papatheodorou
E. Terpos
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 7/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-012-2198-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2013

Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures

Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight

Exercise-induced inhibition of remodelling is focally offset with fatigue fracture in racehorses

Anti-osteoporotic therapy in Denmark—predictors and demographics of poor refill compliance and poor persistence

Correlation of postural balance and knee muscle strength in the sit-to-stand test among women with and without postmenopausal osteoporosis

Non-linear relationship between serum 25-hydroxyvitamin D concentration and subsequent hip fracture